DISCOVERIES (ISSN 2359-7232), 2021, July-September issue

CITATION: 

Submitted: September 08, 2021; Revised: September 23, 2021; Accepted: September 28, 2021; Published: September 28, 2021; 

 GO BACK to 2021, July-September issue

 GO BACK to DISCOVERIES

Heart function assessment during aging in apolipoprotein E knock-out mice

Elisa A. Liehn (1,2,3,*), Ana-Mihaela Lupan (4), Rodica Diaconu (1,2), Mihai Ioana (1), Ioana Streata (1), Catalin Manole (3), Alexandrina Burlacu (4)

(1) Human Genetic Laboratory, University of Medicine and Pharmacy of Craiova, Craiova, Romania

(2) Department of Cardiology, Angiology and Intensive Care, Medical Faculty, University Hospital Aachen, Aachen, Germany

(3) Victor Babes National Institute of Pathology, Bucharest, Romania 

(4) Nicolae Simionescu Institute of Cellular Biology and Pathology, Bucharest, Romania

*Corresponding authors: Dr. Elisa A. Liehn, Department of Cardiology, Angiology and Intensive Care, Medical Faculty, University Hospital Aachen, Germany; Phone: +49-241-80 35983; Email: eliehn@ukaachen.de

Disclosure: Corresponding author, Prof. Elisa A Liehn, is a Senior Editor of the journal Discoveires. This article had 2 Editors assigned, namely Professor Bhanu P. Jena (USA) and Prof. Damodar Gupta (India).

Abstract

BACKGROUND: Apolipoprotein (apo) E isoforms have strong correlations with metabolic and cardiovascular diseases. However, it is not clear if apoE has a role in development of non-ischemic cardiomyopathy. Our study aims to analyze the involvement of apoE in non-ischemic cardiomyopathy.

METHODS AND RESULTS: Serial echo-cardiographic measurements were performed in old wildtype and apoE deficient (apoE-/-) mice. Morphological and functional cardiac parameters were in normal range in both groups at the age of 12 month. At the age of 18 months, both groups had shown ventricular dilation and increased heart rates. However, the apoE-/- mice presented signs of diastolic dysfunction by hypertrophic changes in left ventricle, due probably to arterial hypertension. The right ventricle was not affected by age or genotype. 

CONCLUSION: Even in the absence of high fat diet, apoE deficiency in mice induces mild changes in the cardiac function of the left ventricle during aging, by developing diastolic dysfunction, which leads to heart failure with preserved ejection fraction. However, further studies are necessary to conclude over the role of apoE in cardiac physiology and its involvement in development of heart failure.

Access full text of the manuscript here: Full text (pdf)

References

1. Mahley, R. W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240 (4852), 622-30. 

2. Liehn, E. A.; Ponomariov, V.; Diaconu, R.; Streata, I.; Ioana, M.; Crespo-Avilan, G. E.; Hernandez-Resendiz, S.; Cabrera-Fuentes, H. A., Apolipoprotein E in Cardiovascular Diseases: Novel Aspects of an Old-fashioned Enigma. Archives of medical research 2018, 49 (8), 522-529. 

3. Cornelissen, A.; Simsekyilmaz, S.; Liehn, E.; Rusu, M.; Schaaps, N.; Afify, M.; Florescu, R.; Almalla, M.; Borinski, M.; Vogt, F., Apolipoprotein E deficient rats generated via zinc-finger nucleases exhibit pronounced in-stent restenosis. Sci Rep 2019, 9 (1), 18153. 

4. Castano, D.; Rattanasopa, C.; Monteiro-Cardoso, V. F.; Corliano, M.; Liu, Y.; Zhong, S.; Rusu, M.; Liehn, E. A.; Singaraja, R. R., Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Adv Drug Deliv Rev 2020, 159, 54-93. 

5. Wang, X. L.; McCredie, R. M.; Wilcken, D. E., Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995, 15 (8), 1030-4. 

6. Abondio, P.; Sazzini, M.; Garagnani, P.; Boattini, A.; Monti, D.; Franceschi, C.; Luiselli, D.; Giuliani, C., The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity. Genes (Basel) 2019, 10 (3). 

7. Vogel, T.; Guo, N. H.; Guy, R.; Drezlich, N.; Krutzsch, H. C.; Blake, D. A.; Panet, A.; Roberts, D. D., Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994, 54 (3), 299-308. 

8. Lynch, J. R.; Tang, W.; Wang, H.; Vitek, M. P.; Bennett, E. R.; Sullivan, P. M.; Warner, D. S.; Laskowitz, D. T., APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003, 278 (49), 48529-33. 

9. Zito, G.; Polimanti, R.; Panetta, V.; Ventriglia, M.; Salustri, C.; Siotto, M. C.; Moffa, F.; Altamura, C.; Vernieri, F.; Lupoi, D.; Cassetta, E.; Rossini, P. M.; Squitti, R., Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia. Rejuvenation Res 2013, 16 (1), 51-6. 

10. Asaro, A.; Carlo-Spiewok, A. S.; Malik, A. R.; Rothe, M.; Schipke, C. G.; Peters, O.; Heeren, J.; Willnow, T. E., Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling. Alzheimers Dement 2020, 16 (9), 1248-1258. 

11. Wang, C.; Zhang, M.; Garcia, G., Jr.; Tian, E.; Cui, Q.; Chen, X.; Sun, G.; Wang, J.; Arumugaswami, V.; Shi, Y., ApoE- Isoform- Dependent SARS- CoV-2 Neuro-tropism and Cellular Response. Cell Stem Cell 2021, 28 (2), 331-342 e5. 

12. Gkouskou, K.; Vasilogiannakopoulou, T.; Andreakos, E.; Davanos, N.; Gazouli, M.; Sanoudou, D.; Eliopoulos, A. G., COVID-19 enters the expanding network of apolipoprotein E4-related pathologies. Redox Biol 2021, 41, 101938. 

13. Hubacek, J. A.; Dlouha, L.; Dusek, L.; Majek, O.; Adamkova, V., Apolipoprotein E4 Allele in Subjects with COVID-19. Gerontology 2021, 67 (3), 320-322. 

14. Bhatt, K.; Agolli, A.; Patel, M. H.; Garimella, R.; Devi, M.; Garcia, E.; Amin, H.; Domingue, C.; Guerra Del Castillo, R.; Sanchez-Gonzalez, M., High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova) 2021, 9 (1), e126. 

15. Waleed, R. M.; Sehar, I.; Iftikhar, W.; Khan, H. S., Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications. Discoveries (Craiova) 2020, 8 (4), e117. 

16. Jurkovicova, D.; Goncalvesova, E.; Sedlakova, B.; Hudecova, S.; Fabian, J.; Krizanova, O., Is the ApoE polymorphism associated with dilated cardiomyopathy? Gen Physiol Biophys 2006, 25 (1), 3-10.

17. Alameddine, F. M.; Zafari, A. M., Genetic polymorphisms and oxidative stress in heart failure. Congest Heart Fail 2002, 8 (3), 157-64, 172. 

18. Schumacher, D.; Curaj, A.; Staudt, M.; Cordes, F.; Dumitrascu, A. R.; Rolles, B.; Beckers, C.; Soppert, J.; Rusu, M.; Simsekyilmaz, S.; Kneizeh, K.; Ramachandra, C. J. A.; Hausenloy, D. J.; Liehn, E. A., Phosphatidylserine Supplementation as a Novel Strategy for Reducing Myocardial Infarct Size and Preventing Adverse Left Ventricular Remodeling. Int J Mol Sci 2021, 22 (9). 

19. Schumacher, D.; Curaj, A.; Simsekyilmaz, S.; Schober, A.; Liehn, E. A.; Mause, S. F., miR155 Deficiency Reduces Myofibroblast Density but Fails to Improve Cardiac Function after Myocardial Infarction in Dyslipidemic Mouse Model. Int J Mol Sci 2021, 22 (11).

20. Diaconu, R.; Schaaps, N.; Afify, M.; Boor, P.; Cornelissen, A.; Florescu, R.; Simsekyilmaz, S.; El-Khoury, T.; Schumacher, D.; Ioana, M.; Streata, I.; Militaru, C.; Donoiu, I.; Vogt, F.; Liehn, E. A., Apolipoprotein E4 is Associated with Right Ventricular Dysfunction in Dilated Cardiomyopathy-An Animal and In-Human Comparative Study. Int. J. Mol. Sci. 2021, 22. 

21. Buzello, M.; Tornig, J.; Faulhaber, J.; Ehmke, H.; Ritz, E.; Amann, K., The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003, 14 (2), 311-6.  

22. Lo Sasso, G.; Schlage, W. K.; Boue, S.; Veljkovic, E.; Peitsch, M. C.; Hoeng, J., The Apoe(-/-) mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. J Transl Med 2016, 14 (1), 146. 

23. Getz, G. S.; Reardon, C. A., ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis. J Lipid Res 2016, 57 (5), 758-66. 

24. Vasquez, E. C.; Peotta, V. A.; Gava, A. L.; Pereira, T. M.; Meyrelles, S. S., Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci 2012, 19, 22.

25. Peng, W.; Liu, J. A.; Chen, G.; Zheng, M.; Zhang, L.; Li, A.; Zhou, Y.; Li, J.; Li, G.; Wang, Y., The correlation between ApoE gene polymorphism and non-ischemic chronic heart failure. Int. J. Clin. Exp. Med. 2017, 10 (12), 16809-16814.

26. DeKroon, R. M.; Mihovilovic, M.; Goodger, Z. V.; Robinette, J. B.; Sullivan, P. M.; Saunders, A. M.; Strittmatter, W. J., ApoE genotype-specific inhibition of apoptosis. J Lipid Res 2003, 44 (8), 1566-73. 

27. Diaconu, R.; Donoiu, I.; Mirea, O.; Balseanu, T. A., Testosterone, cardiomyo-pathies, and heart failure: a narrative review. Asian J Androl 2021, 23 (4), 348-356. 

28. Zachowski, A., Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 1993, 294 ( Pt 1), 1-14. 

29. Wood, W. G.; Igbavboa, U.; Muller, W. E.; Eckert, G. P., Cholesterol asymmetry in synaptic plasma membranes. J Neurochem 2011, 116 (5), 684-9.  

30. Cappetta, D.; Esposito, G.; Piegari, E.; Russo, R.; Ciuffreda, L. P.; Rivellino, A.; Berrino, L.; Rossi, F.; De Angelis, A.; Urbanek, K., SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Int J Cardiol 2016, 205, 99-110. 

31. Abdalla, S.; Fu, X.; Elzahwy, S. S.; Klaetschke, K.; Streichert, T.; Quitterer, U., Up-regulation of the cardiac lipid metabolism at the onset of heart failure. Cardiovasc Hematol Agents Med Chem 2011, 9 (3), 190-206. 

32. Kim, S.; Dugail, I.; Standridge, M.; Claycombe, K.; Chun, J.; Moustaid-Moussa, N., Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c. Biochem J 2001, 357 (Pt 3), 899-904. 

33. Hongo, M.; Ishizaka, N.; Furuta, K.; Yahagi, N.; Saito, K.; Sakurai, R.; Matsuzaki, G.; Koike, K.; Nagai, R., Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol 2009, 604 (1-3), 87-92.  

34. Gazewood, J. D.; Turner, P. L., Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. Am Fam Physician 2017, 96 (9), 582-588.

35. Harper, A. R.; Patel, H. C.; Lyon, A. R., Heart failure with preserved ejection fraction. Clin Med (Lond) 2018, 18 (Suppl 2), s24-s29. doi: 10.7861/clinmedicine.18-2-s24.

36. Ahmed, S. N.; Jhaj, R.; Sadasivam, B.; Joshi, R., Regression of the Left Ventricular Hypertrophy in Patients with Essential Hypertension on Standard Drug Therapy. Discoveries (Craiova) 2020, 8 (3), e115.  

37. Umar, S.; Partow-Navid, R.; Ruffenach, G.; Iorga, A.; Moazeni, S.; Eghbali, M., Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy.Biol Sex Differ 2017, 8, 9. 

38. Yao, X.; Gordon, E. M.; Figueroa, D. M.; Barochia, A. V.; Levine, S. J., Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease. Am J Respir Cell Mol Biol 2016, 55 (2), 159-69. 

39. Renshall, L.; Arnold, N.; West, L.; Braithwaite, A.; Pickworth, J.; Walker, R.; Alfaidi, M.; Chamberlain, J.; Casbolt, H.; Thompson, A. A. R.; Holt, C.; Iglarz, M.; Francis, S.; Lawrie, A., Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E(-/-) model of PAH and atherosclerosis. Pulm Circ 2018, 8 (1). 

40. Conceicao, G.; Heinonen, I.; Lourenco, A. P.; Duncker, D. J.; Falcao-Pires, I., Animal models of heart failure with preserved ejection fraction. Neth Heart J 2016, 24 (4), 275-86.